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function of class II, and then focuses on regulation ofJenny Pan-Yun Ting1,3 and John Trowsdale2
1Department of Microbiology and Immunology and expression of MHC class II genes.
The Lineberger Comprehensive Cancer Center
University of North Carolina Class II Region and Genes
Chapel Hill, North Carolina 27599 Theand chains of each class II molecule are encoded
2 Immunology Division by separate genes in the class II region of the MHC
Department of Pathology (Figure 1A) (Allcock et al., 2000; Beck and Trowsdale,
Tennis Court Road, Cambridge CB2 1QP and 1999; Gunther and Walter, 2001). In all cases, except
Cambridge Institute for Medical Research for HLA-DO, the pairs of genes are encoded adjacently.
Hills Road, Cambridge CB2 2XY Some of the genes are duplicated, one copy of each
United Kingdom being functional in the case of DP and DQ. DRB is a
special case, as there can be more than one functional
copy per haplotype, in addition to nonfunctional pseu-
dogenes. Each mouse haplotype also contains twoThe presentation of peptides to T cells by MHC class
H-2M  chain genes, Mb1 and Mb2, both of which areII molecules is of critical importance in specific recog-
functional. Class II sequences obviously arose by re-nition by the immune system. Expression of class II
peated duplications. These must have taken place atmolecules is exquisitely controlled at the transcrip-
several different periods throughout evolution of thetional level. A large set of proteins interact with the
class II gene family. The DM sequence is only weaklypromoters of class II genes. The most important of
related to other class II sequences and probably resultedthese is CIITA, a master controller that orchestrates
from an ancient gene duplication. In contrast, DO se-expression but does not bind directly to the promoter.
quences are 60% identical to DR. DRB loci are highlyThe transcriptosome complex formed at class II pro-
similar and must represent recent duplications.moters is a model for induction of gene expression.
The class II region of the human and rodent MHCs
also harbors a small group of genes involved in antigen
One of the keys to the development of a specific immune
processing, which encode the TAP transporters as well
response to a pathogen is held by MHC class II mole-
as interferon-induced proteasome components. Some
cules (Cresswell, 1994; Nelson and Fremont, 1999). Un-
class I genes are tightly linked to the class II region, at
like class I membrane glycoproteins, which are widely
the centromeric end of the MHC, in rodents, but not in
expressed, class II molecules are generally restricted to
humans. This end of the extended class II region also
a subset of antigen presenting cells, such as macro-
contains the gene for TAPASIN, which is involved in
phages, dendritic cells, and B cells. Their expression
antigen processing for loading class I molecules.
can be induced on other cells types after stimulation
A feature of the MHC is the high degree of linkage
with cytokines such as interferon . MHC class II mole-
disequilibrium across the complex, and the region is
cules are responsible for presenting peptides derived
divided into extended units, or haplotypes (Dawkins et
from extracellular pathogens to T cells bearing the CD4
al., 1999). It is not established whether this is maintained
marker. There are three classical class II molecules in
by selection, polarized recombination, or founder ef-
man: HLA-DP, -DQ, and -DR. Mice only express proteins
fects, but genetic recombination in the MHC class II
orthologous to the last two, A and E, respectively. In
region is highly focused into hotspots (Cullen et al., 1997;
addition to these structures, both species encode so-
Jeffreys et al., 2001). In terms of class II, explanations
called nonclassical molecules, namely HLA-DM and -DO
could be invoked for maintaining certain combinations
in man, and M and O in mouse. These molecules do not
of alleles of different genes in cis relationship. Both
normally reside at the cell surface, and they do not
chains of HLA-DQ and H-2A are polymorphic, and partic-
present antigens; instead, they modulate binding of pep-
ular DQ and H-2A  and  chains do not pair efficiently.
tides to the classical structures. Each class II molecule
In most populations studied to date, one rarely finds 
is a heterodimer of an  chain and a  chain. The tran-
and  alleles encoding these unstable heterodimers on
scriptional control of this family of genes has been ex-
the same haplotype. For example, DQw1-associated 
tensively studied. Numerous DNA binding transcription
chain is not found together with a DQw-2, -3, or -4
factors as well as a master coactivator (CIITA, class II
associated  chain and vice versa. The haplotypes con-
transactivator) have been identified. A clear picture of
taining these unstable heterodimers are generally
the roles of these factors in the induction of chromatin
thought of as “forbidden.” Some exceptions to this gen-
changes and in the formation of an active transcripto-
eral rule may be identified, especially in small isolated
some has emerged, rendering this a model system to
populations (Grahovac et al., 1998).
study these issues. In addition, mounting evidence
shows that the regulation of class II MHC genes is highly
Class II Proteinsrelevant to some important diseases. This review pro-
Each class II heterodimer consists of two integral mem-vides a brief background to the genetics, structure, and
brane proteins of around 26 kDa (Figure 1B). The differ-
ences in size of the  (32 kDa) and  (29 kDa) chains
are mainly attributed to differences in N-linked glycosyl-3 Correspondence: panyun@med.unc.edu
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side chains, they confer sequence-independent binding.
This may explain how class II molecules can bind multi-
ple peptides with high affinity and low specificity. The
three-dimensional structure of the nonclassical class II
molecule, HLA-DM, reveals its unique function (Alfonso
and Karlsson, 2000; Mosyak et al., 1998). The peptide
binding site is altered to an almost fully closed groove,
and the  helixes of the 1 and 1 domains contact
each other over the first and last thirds of their length.
A cavity remains at the center of the membrane-distal
portion of the molecule, forming a deep, polar pocket,
10 A˚ wide and 10 A˚ deep. This pocket is conserved
in orthologous molecules from other species, such as
H-2M. It could bind the end of a peptide, but is not as
large as the lipid binding CD1 pocket. The molecule also
has a tryptophan-rich lateral surface that may bind the
other nonclassical class II molecule, HLA-DO. MHC
class II molecules pack as pairs of heterodimers in some
crystals, and the possibility of “dimers of dimers” form-
ing at the cell surface has fuelled speculation about
the stoichiometry of interaction with T cell receptors.
Evidence for dimer pairs is controversial (Schafer et al.,
1995).
Polymorphism
Classical class II sequences exhibit an extraordinary
degree of variation that is concentrated on the amino
Figure 1. Genetics and Loading of MHC Class II acid residues that shape the peptide binding site. The
(A) Schematic maps of the MHC class II regions in man and mouse. involvement of selection in the maintenance of the poly-
The main genes are shown, including classical class II molecules morphism is suggested by the finding of a high level of
(yellow). Pseudogenes are hatched. Nonclassical class II genes are
nonsynonymous codon changes. This is in contrast topink (DO) and dark blue (DM). Antigen-processing genes for loading
most other genes, as well as the membrane-proximalpeptides onto class I molecules are in purple and green.
(B) Simplified mechanism for DM-mediated peptide exchange on domains (2 and 2), where synonymous variation nor-
DR molecules. Class II dimers assemble with Ii in the ER to form a mally predominates. Except for DQA and Aa, the se-
nonameric complex of an Ii trimer and three class II dimers. The quences encoding the  chains are generally less vari-
complexes are transported to specialized lysosome-like compart- able. There are few alleles of Ea and DRA, with
ments for loading of antigenic peptides. In these vesicles, the Ii
conservative amino acid changes. Generation of thechain is hydrolyzed to leave class II bound to the Ii derivative, CLIP.
polymorphism could be due to point mutation, but theDO (not shown) is also associated with DM in the ER and it travels
with DM. Peptide exchange is catalyzed by DM, by stabilizing the mutation rate is not especially inflated compared to
transition state. more conventional genes. It is likely that “allele conver-
sion” (double crossover to replace a short section of an
allele) has taken place repeatedly, because the alleles
have the semblance of being “patchworks” of eachation. The  and  chains of all classical class II mole-
other. Some alleles could have arisen by recombination,cules have the same overall conformation, each con-
using single crossovers. Gene conversion has also beensisting of two extracellular domains, 1 and 2, and
proposed as a possible mechanism for incorporating1 and 2, respectively. The membrane-distal domains
sequences from other linked class II genes. There iscombine to form a single peptide binding site composed
evidence for this mechanism in conversion of class Iof two antiparallel -helical loops supported by a plat-
sequences in mice.form of eight antiparallel  strands. These domains fea-
The nonclassical class II molecules are relatively in-ture the high level of polymorphism exhibited by MHC
variant. Some alleles of both HLA-DM and -DO havemolecules. A conserved disulfide bond connects the
been described, but these vary by small numbers of-helical region of the 1 domain to a strand in the
amino acids and, so far, have no known functional signif-platform floor (10cys to 78cys). The DM molecule
icance.contains two additional disulfide bonds ( 24-79 and 
25-35).
The groove of class II, like that of class I molecules, Peptide Loading, Ii, and the Role of DM
Soon after synthesis, classical class II molecules associ-is capable of binding a wide range of peptides. Peptides
bind to class II in an extended conformation. In contrast ate in the endoplasmic reticulum (ER) with a third pro-
tein, a type II (i.e., of inverted orientation) membraneto class I, the N and C termini of class II-bound peptides
may extend beyond the ends of the groove. The peptide glycoprotein called invariant chain (Ii) (Cresswell, 1996)
(Figure 1B). The combined proteins form a nonamericis held by a series of hydrogen bonds between the pep-
tide backbone and conserved amino acid side chains structure, consisting of three Ii chains, arranged as a
core, surrounded by three classical class II heterodi-lining the groove. Since the bonds do not involve peptide
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mers. The grooves of the class II molecules are occu- cules CD63 and CD82, which may also play a role in
pied, in the nonamer, by a section of the Ii chain called the later stages of class II maturation (Hammond et al.,
CLIP. This may help to avoid loading of the groove with 1998).
ER-resident proteins, as is the case for class I. The main
function of invariant chain seems to be as a chaperone to The Role of DO
ensure correct folding and egress of class II. It contains a The second nonclassical class II molecule HLA-DO
di-leucine targeting signal in its cytoplasmic tail which arose at a later stage of evolution to HLA-DM (Haas et al.,
helps to divert the nonamer from the default secretory 1987). DO is also monomorphic and, like DM, it resides in
pathway to lysosomal-like vesicles, called MIIC (for MHC MIICs. It appears to require association with DM to ac-
class II compartment), where peptide is eventually cess these vesicles. In some hands, DO appears to
loaded. Before this can take place, however, Ii is de- counteract the effect of DM, in a pH-dependent manner.
graded by lysosomal proteases such as cathepsin L Its effects may be optimal at pH 6, blocking peptide
and S. It is progressively cleaved, leaving just the CLIP exchange in early endosomes. DO does not work as
fragment itself occupying the groove. well at pH 5, the condition which favors DM-mediated
The MIICs are depots where the class II molecules, peptide exchange in MIIC vesicles. A simple model to
groomed in this way, meet up with antigenic peptides account for the action of DO would be for both DR and
that come from degradation of exogenous proteins. DO to compete for the same site on DM.
These may be internalized either by endocytosis or by There is no consensus on the precise function of DO,
interaction with surface receptors on antigen presenting and in some experiments it seems to enhance peptide
cells (APCs). For example, proteins bound to surface exchange (Kropshofer et al., 1999). A clue to the function
antibodies are internalized on B cells. Other cells may of DO may be provided by its expression, which is re-
take up antibody:antigen complexes using the range of stricted mainly to B cells. Indeed, control of transcription
Fc receptors. Lectin-like receptors, such as mannose of DOB may be less dependent on the CIITA transcrip-
receptors, may be invoked to deal with glycoproteins. tion factor and induction by IFN- (see below). In B cells,
Topologically, peptide loading in MIIC vesicles is “out- DO may help to refine peptide loading to a restricted
side” in that it is separated by membrane from the cyto- subset of class II molecules.
plasm.
Efficient exchange of CLIP for antigenic peptides is Expression of Class II
mediated by DM (Sanderson and Trowsdale, 1995). The Class II molecules are constitutively expressed on cells
structure of the DM molecule reveals that it is highly that serve as APCs for CD4 T cells, such as macro-
unlikely to bind peptides and the groove of DM is effec- phages, monocytes, dendritic cells, and B cells; they
tively sealed (Mosyak et al., 1998). Moreover, at steady may be induced on other cells by IFN-. Class II expres-
state, most of the DM molecules reside in the MIIC sion is also modulated by other agents, such as IL-4,
vesicles. DM binds transiently to class II:CLIP and stabi- IL-10, IFN-/, TNF, and glucocorticoids. Concomitant
lizes an intermediate state where CLIP is released, expression of all three classical molecules is usually
allowing other peptides to bind. A speculative model observed, although exceptions exist. Some B cells ex-
proposes that DM contacts DR “shoulder to shoulder”: a press solely DQ and others only DR. This raises the
conserved tryptophan residue (62 Trp) in DM interacts important question of whether the different class II iso-
with 51 Phe of DR, at the extended strand where the
types exert distinct T cell functions, or whether they
class II groove differs from that of class I, near pocket
merely enlarge the peptide binding repertoire. Distinct
1 (Nelson and Fremont, 1999; Doebele et al., 2000). This
functions have been suggested for HLA-DQ and -DR, theinteraction could result in destabilization of several pep-
former being more likely to “suppress” some responsestide:MHC bonds, lowering the free energy barrier to pep-
(Hirayama et al., 1987). These observations may enjoytide dissociation. DM stabilizes the open transition con-
renewed interest now that suppression of T cell re-formation of DR, favoring faster peptide association, in
sponses by T cells has finally gained credibility. Thisthe MIIC environment that is rich in imported, antigenic
issue is of crucial importance in view of the associationpeptides. The class II molecule may be quite flexible
of class II loci with a vast array of autoimmune condi-around the first, hydrophobic pocket in the absence of
tions—an association which is still not fully explained.bound antigenic peptide. A more rigid conformation is
Clearly, precise regulation of class II expression isprobably generated after filling of pocket 1, which would
critical. To address this, much effort has been devotedrender the molecule less susceptible to the effects of
to the analysis of MHC class II promoters and the tran-DM (Chou and Sadegh-Nasseri, 2000). The side chains
scription factors that are involved in their regulation.in CLIP could be structured in such a way as to permit
The following sections are devoted to these aspects ofbinding to all classical class II molecules but release
MHC class II.from the groove under appropriate conditions, such as
in the presence of DM and in the low pH of the MIIC
Promoter Motifsvesicle. CLIP can be regarded therefore as a disposable
One of the outstanding features of MHC class II loci isstuffer. Once antigenic peptide is stably bound, DM may
that not only the structural genes, but also the promoterlose its association for class II. Alternatively, DM may
elements, are remarkably conserved. All the classicalbe released at the cell surface, to be retargeted to MIICs.
and nonclassical class II promoters, including that forThe cytoplasmic tail of DM contains a tyrosine-based
Ii, contain three elements—S (also W or Z), X, and Y—targeting signal (Copier et al., 1996).
which are necessary for optimal constitutive and cyto-The complex of classical and nonclassical class II
molecules in the MIICs associates with tetraspan mole- kine-induced gene expression. These sequences have
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Table 1. Representative MHC Class II Defective Cell Lines
Complementation Patient-derived In vitro MHCII promoter Genetic RFX
group cell lines mutants MHCII Ag activity/mRNA defect binding Promoter occupancy
A BLS-2, BCH1,2 RJ2.2.5 — — MHC2TA  
B BLS-1, Ra — — — RFXANK — —
C SJO G1B (IFN-) — — RFX5 — —
D DA, ABI 6.1.6 — — RFXAP — —
Atypical lines
G3A (IFN-) — — unknown  —
KEN/KER  for DRB, DQB, DPA — unknown   for DRB, DQB, DPA
been extensively reviewed elsewhere (Benoist and twins (KEN/KER) in whose B cells DRB, DQB, and DPA
are not expressed have been reported (Douhan et al.,Mathis, 1990; Glimcher and Kara, 1992), and will not
be discussed here in detail. In addition to sequence 1996; Hauber et al., 1995). The in vitro generated MHC
class II/ cell line, G3A, also represents an atypicalconservation, the stereospecific alignment (i.e., DNA he-
lical orientation and spacing) of the three elements is case. In this cell line, although X and Y binding proteins
appear to be normal, CIITA induction by IFN- is notalso critical (Harton and Ting, 2000). These data strongly
implicate a model in which proteins binding to the S/W, optimal, and the introduction of exogenous MHC2TA
restores class II expression (Chin et al., 1994). ExceptX, and Y elements must bind in a spatially-restricted
fashion to allow direct interactions among them, and/ for these atypical cases, where the genetic defect is
undefined, it is now clear that each complementationor interaction with a coactivator to form the active tran-
scriptosome complex (see below). group has a specific defect in a transcription factor that
is necessary for MHC class II expression (see below)
(Reith and Mach, 2001).Bare Lymphocyte Syndrome (BLS)
A discussion of the field of MHC class II regulation would
not be complete without considering the heterogeneous Transcription Factors and Coactivator
The initial characterizations of proteins that bind directlygroup of genetic disorders, collectively called BLS or
MHC class II deficiency (MIM209920). Several excellent to MHC class II promoters identified both constitutively
and ubiquitously expressed factors (Figure 2A). The Yreviews have appeared elsewhere (DeSandro et al.,
1999; Reith and Mach, 2001), and only a brief discussion element, a canonical CCAAT box, is bound by NF-Y/
CBF, a molecule that is conserved from yeast to humandirectly relevant to this review follows. BLS is a rare
immunodeficiency inherited as an autosomal recessive (Maity and de Crombrugghe, 1998; Mantovani, 1999).
NF-Y binds to DNA as a heterotrimer consisting of A,disease; it arises due to a high degree of consanguinity in
patients’ families. Patients typically suffer from frequent, B, and C subunits. The B and C subunits contain histone-
fold motifs that are similar to eukaryotic histones H2Asevere bacterial, fungal, or viral infections. Cells from
the typical BLS patient lack constitutive and inducible and H2B and an archaebacterial histone-like protein.
The RFX factor, also a trimer, binds to the X1 elementexpression of all MHC class II genes, including the 
and  chains of DR, DP, and DQ. These patients exhibit (Durand et al., 1997; Masternak et al., 1998; Nagarajan
et al., 1999; Steimle et al., 1995). It consists of RFXANK/severely hampered T cell activation and greatly reduced
CD4 cells, although a recent report has described a RFXB, RFX5, and RFXAP, and defects in each define the
BLS complementation groups B, C, and D, respectivelyfamily with a L469P mutation in CIITA that presents as
an attenuated clinical course accompanied by residual (Table 1). RFX5 belongs to the RFX family of DNA binding
proteins, and it was identified by complementation clon-MHC class II expression (Wiszniewski et al., 2001). In
all cases that were tested, the MHC class II genes were ing using the MHC class II defective cell line, SJO
(Steimle et al., 1995). RFX5 has a DNA binding domainnot structurally defective, since fusions between defec-
tive cells and a normal cell invariably lead to surface and a C-terminal domain that interacts with NF-Y (Reith
and Mach, 2001). The other two components of the com-expression of class II from the genotypes of both cells.
EBV-transformed B cell lines obtained from these pa- plex that bind X1 were identified by biochemical purifi-
cation. RFXANK/RFXB has ankyrin repeats typicallytients have proven invaluable in deciphering the regula-
tory pathway of MHC class II genes (Table 1; partly thought of as mediating protein-protein interactions.
These repeats provide an interaction platform to assem-adapted from Reith and Mach, 2001, with permission,
from the Annual Review of Immunology, Volume 19. ble the RFX complex by interacting with RFXAP, RFX5,
and CIITA. A single nucleotide mutation in the ankyrin2001 by Annual Reviews, www.annualreviews.org). In
addition to B cell lines obtained from BLS patients, sev- repeats results in abrogation of the RFXANK-RFXAP
interaction in a BLS cell line, affirming the importanceeral mutant cell lines have been generated in vitro, pri-
marily based on the lack either of constitutive MHC of these repeats (Nekrep et al., 2001). RFXAP, or RFX-
associated protein, contains acidic, basic, and gluta-class II expression or of IFN--induced MHC class II
expression. Somatic cell fusions of BLS-derived cell mine-rich sequences (Masternak et al., 1998). A recent
report has shown that only the C terminus of RFXAP islines and/or in vitro generated class II-negative cell lines
have led to the delineation of four complementation essential for function, and different segments within this
region are required for allele-specific class II expressiongroups. Additionally, two atypical cases represented by
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Figure 2. Molecular Regulation of MHC
Class II
(A) A prototype MHC class II promoter and
transcriptosome. The MHC class II promoter,
its cognate DNA binding factors (NF-Y,
CREB, and RFX), and the coactivator, CIITA,
are shown. Positioning of the RFX subunits
is drawn according to Westerheide and Boss
(1999). Interactions among the DNA binding
factors, CIITA, general transcription factors
(TAFs), and HATs are indicated. The tran-
scriptional elongation factor, pTEFb, is also
shown.
(B) Negative and positive regulation of MHC
class II and CIITA. Positive or negative regula-
tory processes typically target CIITA tran-
scription or protein, which then targets MHC
class II expression. (Left) Positive regulators
include IFN-, IL-4, LPS, and IL-1. The path-
way for IFN- is best delineated, involving
the induction of P3 through STAT1, and the
induction of P4 through IRF-1, IRF-2, and
STAT1. (Right) Negative regulators include
TGF-, IL-10, IFN-, and nitric oxide. Sup-
pression of CIITA P4 expression by TGF-
requires SMAD3, while suppression of CIITA
function by IFN- requires ISGF3. It is unclear
which promoters are affected by IL-10, NO,
and IFN-. PGE inhibits CIITA protein func-
tion by PKA-mediated phosphorylation. In addition, epigenetic events such as histone deacetylation and DNA methylation, and developmentally
expressed molecules such as BLIMP1, negatively regulate CIITA production. HDACs also controls MHC class II expression through a CIITA-
independent pathway. Dark blue ovals represent cell nuclei.
(Peretti et al., 2001). In addition to its specificity for that precisely parallels that of MHC class II synthesis.
Likewise, class II cells, such as B cells, monocytes,the X1 element, the RFX complex also binds the S/W
dendritic cells, and human activated T cells, expresselement (Jabrane-Ferrat et al., 1996). Finally, a protein
CIITA (Harton and Ting, 2000; Reith and Mach, 2001).which binds to the X2 box was purified and then identi-
Additionally, an in vivo study has shown that the expres-fied as CREB (Moreno et al., 1999). CREB is bound to
sion of CIITA under inflammatory transplantation condi-the MHC class II promoter as shown by the chromatin
tions parallels the expression of MHC class II (Sims andimmunoprecipitation (ChIP) assay. It also interacts with
Halloran, 1999). CIITA transcription is upregulated byCIITA and RFX, forming a final anchor in the large tran-
IFN-, LPS, and IL-4, and is downregulated by IFN-,scriptosome complex.
IL-10, nitric oxide, and TGF (Figure 2B) (Harton andThe DNA binding proteins mentioned above are all
Ting, 2000; Reith and Mach, 2001). The induction byconstitutively expressed, which cannot explain the cell-
IFN- and downregulation by TGF are best workedspecific, cytokine-induced, and developmentally regu-
out; the former is mediated by IRF-1, IRF-2, USF-1, andlated expression of MHC class II genes. The isolation
STAT1, and the latter by Smad3 (Dong et al., 2001; Xiof the MHC class II transactivator gene (MHC2TA) solved
et al., 1999). The regulation of CIITA expression occursmuch of this problem, and remains one of the seminal
primarily at the transcriptional level; an exception is thediscoveries in the field (Steimle et al., 1993). MHC2TA
suppression of CIITA activity by prostaglandins in my-was identified by complementation cloning of the
eloid-monocytic cells when PGE-induced, cAMP-RJ2.2.5 cell line (see Table 1) using an EBV-based epi-
dependent PKA causes the phosphorylation of CIITA (Lisomal cDNA library. Complementation of RJ2.2.5 with
et al., 2001). Developmentally, CIITA suppression alsoa vector containing MHC2TA, encoding CIITA, resulted
occurs when B cells differentiate into plasma cells; thisin the expression of surface class II antigens. Because
is attributed partly to the BLIMP-1/PRD transcriptionCIITA does not bind DNA, it is an authentic transcrip-
factor expressed in plasma cells (Ghosh et al., 2001;tional coactivator, defined as a transcription factor that
Piskurich et al., 2000). Another level of regulation is atmediates its function through interaction with other pro-
the epigenetic level, where DNA methylation of the CIITAteins. Long thought to be unique, CIITA is now recog-
promoter suppresses its expression in trophoblastsnized as a founding member of the NACHT protein fam-
(Morris et al., 2000), while inhibitors of histone deacety-ily, which share several domains, including NTPase and
lases enhance MHC class II expression through bothWalker A and B motifs, and have roles in inflammatory
CIITA-dependent and -independent pathways (Magnerresponses and apoptosis (Koonin and Aravind, 2000).
et al., 2000).
Expression and Regulation of CIITA Cell-Specific Promoters and Isoforms of CIITA
Unlike RFX and NF-Y, CIITA exhibits cell-specific, cyto- An area of research that has received much attention
is the finding that MHC2TA contains multiple promoterskine-inducible, and differentiation-specific expression
Cell
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Figure 3. Regulation, Structure, and Function of CIITA
(A) Promoters of MHC2TA and structure of CIITA. The promoter of the MHC2TA (top) shows the different regulatory elements (arrows) found
in the various promoters. A distal GAS site which responds to STAT1 is shown, although the precise location is unclear. The structure of
CIITA protein (bottom) shows the different domains described in the text.
(B) Different states of the MHC class II transcriptosome. (a) In B cells, CIITA is not required for occupancy of the promoter by RFX and NF-Y.
(b) In IFN- responsive cells, the promoter is bare or weakly bound in the absence of CIITA. (c) In cells which are not known to express class
II antigens, such as trophoblasts, the promoter is silenced by DNA methylation. (d) The presence of CIITA in B cells causes H3 and H4
acetylation. Whether this is through tethered HATs, or through CIITA’s intrinsic HAT activity, or both, is unclear. (e) Introduction of CIITA or
induction by IFN- causes promoter occupancy and H3/H4 acetylation in IFN- responsive cells. YY1, a known HDAC, blocks IFN--induced
class II mRNA expression through a YY1 binding site found in the first exon.
directing the synthesis of at least three different 5 cod- tinction can be reversed by an inhibitor of histone de-
acetylases (HDACs). The extra 94 aa found in this iso-ing sequences (Muhlethaler-Mottet et al., 1997). This
indicates that CIITA function is regulated in a complex form, as compared to the P3 isoform, encodes a
caspase activation and recruiting domain (CARD) (Nick-fashion, controlled by both cell-specific promoters as
well as cell-specific isoforms. Although the precise ex- erson et al., 2001). This isoform is quantitatively more
efficient than the P3 isoform in activating a DR promoter,pression of these isoforms is still undergoing revision,
the current understanding is summarized as follows perhaps explaining the higher concentration of class II
molecules on dendritic cells. P2 is not clearly defined.(Figure 3A, top). Promoter 1 (referred to as P1) is used
in dendritic cells and leads predominantly to the expres- P3 causes the generation of a 124 kDa isoform which
is constitutively expressed in B cells. A short promotersion of the longest isoform of 132 kDa (Landmann et
al., 2001). It is extinguished when immature dendritic region of 200 bp for P3 is required for expression in
B cells; two in vivo footprints in this region correspondcells differentiate into a mature phenotype, and the ex-
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to two functional promoter elements, ARE-1 (a TEF-like theme is the shuttling of CIITA in and out of the nucleus,
as evidenced by its sensitivity to the nuclear exportelement) and ARE-2 (Ghosh et al., 1999). On the other
hand, a long promoter for P3 that extends 6 kb upstream inhibitor, leptomycin B, and by the identification of two
sequences that are similar to nuclear export motifsis required for activation in IFN--treated macrophage/
monocytic lines in a STAT1-dependent fashion, and it which interact with the nuclear export protein CRM1.
is also abundantly expressed in IFN- activated melano-
mas and glioblastomas (Piskurich et al. 1999, Deffrennes Protein Complex Formation and Transcriptosome
et al., 2001; Goodwin et al., 2001). It is also expressed Assembly
by immature dendritic cells, and is similarly silenced Extensive protein-protein interactions involving all of the
upon maturation (Landmann et al., 2001). P4, originally players described above occur across the MHC class
suggested to represent the primary IFN--inducible pro- II promoter to form an active and more stabilized tran-
moter, is responsive to a combination of IRF-1, STAT1, scriptosome (Figure 2A). Several reports have demon-
and USF transcription factors, and produces the short- strated interactions among peptides that bind to the X
est isoform of 121 kDa. However, a targeted deletion of elements and NF-Y, and binding at these sites in an in
this promoter region in mice showed that it is crucial vitro gel shift assay has a mutually enhancing effect on
for the expression of MHC class II in nonhematopoietic protein-DNA interactions (Harton and Ting, 2000; Reith
cells, including cortical thymic epithelial cells, but not and Mach, 2001). Analysis of the X2 binding protein,
for hematopoietic cells (Waldburger et al., 2001). The CREB, shows that it also interacts with RFX to form a
most straightforward explanation is that this form is nor- stable complex. These interactions are in agreement
mally not required for CIITA expression in hematopoietic with the analysis of in vivo or genomic footprint analysis
cells, although there is a possibility that other promoter- which allows the visualization of protein-DNA interac-
isoform pairs may have compensated for the loss of this tions in intact cells. These latter studies show that the
form in hematopoietic tissues. in vivo binding of transcription factors to X1 and Y is
In summary, this complex array of MHC2TA promoters interdependent, while occupancy of X2 is dependent on
suggests that the fine-tuning of MHC class II expression binding of both X1 and Y. A generally accepted working
must be crucial to assure a balance of selective immu- model is that NF-Y, RFX, and CREB all interact, and
nity to foreign pathogens/antigens and tolerance to self- this interaction likely promotes the formation of a stable
antigen. The timing and regulation of CIITA isoforms in transcriptosome complex.
distinct tissues have to be tightly regulated to assure From its discovery, it was presumed that CIITA must
proper immune function. The complexity of environmen- interact with the DNA binding transcription factors, since
tal signals, developmental programs, and cell-specific it is not a DNA binding protein. Indeed, several groups
information must be interpreted accurately at the level have used different approaches to reveal such interac-
of MHC2TA regulation to achieve appropriate MHC class tions. CIITA interacts with NF-YB and NF-YC, but only
II expression. weakly with NF-YA; it also interacts with RFXANK/RFXB
and RFX5. In addition, an insightful in vivo approach,
namely the ChIP assay, used to examine protein compo-Structure and Function of CIITA
Structure-function analyses of CIITA have revealed the nents of a transcriptosome, has begun to reveal impor-
tant information. This procedure utilizes antibody di-presence of both conventional domains expected of
transcriptional activators, as well as unorthodox motifs rected at a component of the transcriptosome to pull
down interacting proteins, and hence their respective(see Harton and Ting, 2000) (Figure 3A, bottom). The
acidic domain at the N terminus (residues 1–125) is re- cognate DNA sequences. A ChIP analysis has shown
that CIITA coprecipitates DNA sequences that corre-quired for transactivation function, which may be
achieved by providing an interaction surface for the his- spond to the X and Y elements, and hence CIITA directly
or indirectly interacts with X and Y binding proteinstone acetylase CBP and RFXANK (Fontes et al., 1999;
Kretsovali, 1998; Zhu et al., 2000). This segment also (Masternak et al., 2000).
In addition to the specific players described above,contains an intrinsic histone acetyltransferase (HAT) do-
main (Raval et al., 2001) (see below). A proline-serine- the MHC class II transcriptosome has other interacting
partners. By yeast two-hybrid analysis, CIITA interactsthreonine-rich domain (residues 126–336) that contains
multiple potential phosphorylation sites then follows. with the basal transcription factor TAFII32, a component
of TFIID, and indirect evidence also indicates theThe midsection of the protein contains an unusual se-
quence for a transcription coactivator, the GTP binding involvement of TAFII250 in CIITA-mediated transactiva-
tion. CIITA has also been observed to promote transcrip-domain (residues 337–702), that is involved in protein
self-association and is important in nuclear import (Kret- tional elongation, presumably through its interaction
with cyclin T1, which together with CDK9 forms thesovali et al., 2001; Linhoff et al., 2001; Sisk et al., 2001).
Finally, a leucine-rich region (LRR) that also affects nu- positive transcription elongation factor b (P-TEFb) (Ka-
nazawa et al., 2000). Aside from the interaction of CIITAclear translocation and the self-association process re-
sides at the C terminus. It associates with a 33 kDa with basal transcription factors, NF-Y has been shown
to recruit the TFIID complex and to enhance the affinityprotein; however, the identity and significance of this
protein are presently unclear (Hake et al., 2000). Scat- of holo-TFIID for a MHC class II promoter through inter-
actions with a number of TAFs (Mantovani, 1999). Addi-tered amidst the protein are three nuclear translocation
sequences, including two conventional nuclear localiza- tionally, NF-Y also interacts with histones H3 and H4 as
well as the HAT p300 (Caretti et al., 1999). Notably, CBP,tion sequences (NLS) and a bipartite NLS (Cressman et
al., 1999, 2001; Kretsovali et al., 2001). An emerging a homolog of p300, is a CREB binding protein, and CREB
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binds X2. Whether all these associations occur at the CBP/p300/CAF in promoter assembly will require analy-
sis of the endogenous promoter under most physiologicchromatin level at the MHC class II promoter is an impor-
tant area of investigation. conditions. A recent study has begun to address this
issue by employing the ChIP assay in conjunction with
real time PCR to assess the relationship between his-Chromatin Modification
tone acetylation and CIITA occupancy (Beresford andOne of the hallmarks of gene expression is the alteration
Boss, 2001). They found that the presence of CIITA cor-of chromatin accessibility and DNA methylation status.
related with the acetylation of H3 and H4 at the endoge-Earlier studies of the chromatin structure of MHC class
nous MHC class II promoter in both B cells and an IFN--II promoters utilized the genomic footprinting approach
inducible cell line. This result should be interpreted into show that different subgroups of BLS-derived B cell
light of the in vivo footprint analysis described abovelines differ in the in vivo occupancy of their promoters
where binding of factors to endogenous MHC class IIby DNA binding factors (Figure 3B). In cells lacking RFX,
promoters in B cells does not require CIITA, while CIITAall MHC class II promoters are bare (i.e., in vivo footprints
is required in IFN- responsive cells. This new studyare lacking), while in cells lacking CIITA, the promoters
shows that regardless of cell type, CIITA is essential forare occupied normally (Kara and Glimcher, 1991). This
proper histone acetylation in both cell groups. Thesewould suggest that RFX is crucial for promoter accessi-
results distinguish between factor binding to promotersbility, while CIITA is not. Indeed, in an RFX-defective,
and histone acetylation, and conclude that the formerIFN- responsive cell line (G1B), the promoter is also
can occur without the latter, although transactivationbare despite IFN- treatment, which verifies the impor-
does not occur in the absence of CIITA or histone acet-tant role of the RFX protein in promoter assembly in
ylation (Figure 3B).both constitutive and inducible model systems (Brickey
Finally, the role of histone deacetylase complexeset al., 1999). In contrast, the role of CIITA in promoter
(HDACs) in MHC class II gene control has begun tooccupancy in B cells and in an IFN- inducible system
emerge. The general HDAC inhibitor, TSA, can rescueis in disagreement. In an IFN- inducible system, where
class II expression in tumor cells and mature dendriticCIITA is not expressed, or expressed at a minimal level
cells where CIITA promoters are silenced (Landmann etprior to cytokine treatment, MHC class II promoters are
al., 2001; Magner et al., 2000). Similarly, in a systemminimally occupied; the addition of IFN- causes acces-
where class II expression is silenced in the absencesibility of the promoter in a time-dependent fashion (Har-
of the retinoblastoma protein (Rb), the addition of TSAton and Ting, 2000). This would suggest that CIITA is the
restored expression and YY1 was identified as one ofcrucial factor for promoter accessibility. Indeed, when
the HDACs (Osborne et al., 2001). Prior to the inhibitionCIITA was transfected into MHC class II-negative cells,
of HDAC, the promoter was found to exist in a nucleo-the nonclassical DM as well as Ii promoters became
some-free, DNase hypersensitive configuration, indi-bound by factors. The precise reason for the different
cating that HDAC can exert its effect despite the es-dependency on CIITA between B cells and IFN- respon-
tablishment of a chromatin environment favorable forsive cells remains unresolved. One reasonable model is
transcription initiation, and presumably with proteinsthat the ubiquitous factors such as RFX and/or NF-Y
bound to the promoter. This again suggests that modifi-may be expressed at higher concentrations in B cells,
cation of the acetylation state of histones and bindingwhich obviates the absolute need for CIITA to stabilize
of proteins to the promoter occur independently.the transcriptsome. This possibility was suggested by
a report which noted higher levels of RFX in B cell lines
than in IFN- responsive lines (Moreno et al., 1997). Specificity of CIITA and RFX for MHC
Class II Gene ExpressionDespite these differences, CIITA remains pivotal for the
transcription of MHC class II genes in both B cells and Two questions have been raised regarding the specific-
ity of CIITA and RFX: (1) Do these factors control otherIFN- responsive cells.
How chromatin accessibility occurs over MHC class genes? (2) Does MHC class II expression persist when
either of these factors is missing? The first questionII promoters is an increasing focus of study. Both CIITA
and NF-Y can interact with HATs, the former with p300, has to be considered against the backdrop that the
specificity of transcription factors is frequently invokedCBP, and pCAF, the latter with p300 (Fontes et al., 1999;
Kretsovali, 1998). Cotransfection with CIITA and CBP, when they are first described, but this specificity fails
to withstand more extensive investigation. CIITA haspCAF, or p300 can lead to increased activation of a
MHC class II promoter-reporter construct. Despite this largely escaped this fate, with rare exceptions; many of
its effects are specific for MHC class II molecules or itsenhancement, the HAT domains of CBP and pCAF are
dispensable for this activation (Harton et al., 2001). This associated proteins. This is supported by representation
difference analysis (RDA), which shows that most, if notwould agree with the findings of two reports. The first
shows that CIITA has intrinsic HAT activity, and thus all, of the genes induced by CIITA are within the class
II pathway (Taxman et al., 2000). The control of the DOAmay render other HATs dispensable (Raval et al., 2001).
CIITA’s HAT domain shares sequence homology with and DOB genes by CIITA is less straightforward. Two
reports showed common findings in the regulation ofCBP and can substitute for the HAT function of TAFII250.
A second study found that two acetylated lysine resi- these two genes: the first used the aforementioned RDA
method (Taxman et al., 2000), while the second used adues within CIITA are important for nuclear import and
that CBP and CAF may serve an alternate function in chip array analysis (Nagarajan et al., 2002). Both found
that in B cells, DOA is dependent on CIITA for expres-facilitating CIITA import into the nucleus (Spilianakis et
al., 2000). More detailed analysis of the relevance of sion, while DOB is expressed even in cells lacking CIITA.
Molecular Control and Genetics of MHC Class II
S29
Additionally, DOA and DOB are dependent on RFX for CIITA/ mice used in the first study and found that
gene expression. However, the array analysis accompa- class II expression on dendritic cells is reduced 99% as
nied by real-time PCR showed a 2-fold enhancement of assessed by real-time PCR, and agrees with the notion
DOB in the presence of CIITA, which was not detected of CIITA serving as a master regulator (Landmann et al.,
by RDA. This is reasonable, as the latter is best for 2001).
detecting all-or-none differences, while array analysis The analysis of RFX5/ mice showed class II expres-
detects more quantitative differences. The array paper sion on thymic medulla, mature dendritic cells, and acti-
also showed that the introduction of CIITA into an IFN-- vated B cells, but not B cells or IFN- activated macro-
inducible system does not greatly enhance DOB expres- phages (Clausen et al., 1998). Despite this residual
sion, in contrast to the great enhancement of DOA and expression, both CIITA/ and RFX5/ mice show se-
DRA by CIITA. This agrees with an earlier finding that vere immunodeficiency and CD4 T cell defects, repli-
IFN- likewise significantly induces DOA but not DOB cating the findings in humans. However, the CIITA/
(Tonnelle et al., 1985). It is reasonable to conclude that mice do respond differently from mice lacking A, which
DOB is less affected by CIITA than other class II MHC are generally considered to be class II defective. In the
genes, although an effect can be detected, and that a nonobese diabetes (NOD) model, CIITA/ NOD mice
CIITA-independent pathway exists for its expression. have pancreatic cellular infiltrates, while A/ mice do
To further complicate the picture, CIITA/ mice retain not (Mora et al., 1999), yet neither display symptoms
expression of both H-2OA and B as observed by RT- of diabetes. Whether this difference between the two
PCR. Whether this represents differences between hu- strains can be attributed to residual class II expression,
mans versus mice, in vitro cell lines versus in vivo pri- to other class II-associated genes (Ii, M, O), or to nonas-
mary tissues, or simply RT-PCR versus real-time PCR sociated genes that are selectively controlled by CIITA
is unclear. remains to be determined.
CIITA is known to control a few genes other than MHC
class II, although none are as strongly induced as class Disease and Physiologic Relevance
II genes. Class I MHC promoter and antigen expression The MHC class II loci are associated with more diseases
is enhanced by CIITA in both human and murine lines than any other region of the genome of equivalent size.
(reviewed in van den Elsen and Gobin, 1999). CIITA regu- Class II-related autoimmune conditions are suspected
lation of class I is mapped to a region that has S/W, X, to be due to a failure of tolerance. Expression of class
and Y homologs; ChIP analysis also shows the presence II genes must be tightly and subtly controlled to ensure
of CIITA at the endogenous 2M promoter, which like- appropriate vigorous responses to pathogens while
wise contains X and Y elements (Masternak et al., 2000; minimizing collateral damage to host tissues.
Riegert et al., 1996). A reduction of class I MHC has Considering that CIITA is a master regulator of MHC
been observed in human Group A BLS patients but not class II gene transcription, it represents an ideal target
in CIITA/ mice. The reason for this discrepancy is for pathogens to evade the immune system. Indeed, a
unclear. In addition to class I MHC, a handful of genes variety of pathogens (cytomegalovirus (CMV), Mycobac-
have been found to be downregulated by the presence
terium bovis, Chlamydia, varicella-zoster virus, parain-
of CIITA, including IL-4, fas, and collagen (Gourley and
fluenza virus, and Epstein Barr virus (EBV)) have evolved
Chang, 2001; Sisk et al., 2000; Zhu and Ting, 2001). In all
several pathways to alter the expression of CIITA (re-
these cases, CIITA mediates suppression by squelching
viewed in Harton and Ting, 2000; Reith and Mach, 2001;general HATs. One of these studies compared the defec-
Accolla et al., 2001; see also Gao et al., 2001; Morrison ettive G3A cell line, in which IFN- induction of CIITA
al., 2001). Furthermore, HIV-1 infection also suppressesis suboptimal, to its normal parent, thus allowing the
class II expression by interfering with both CIITA and NF-investigation of endogenous CIITA in gene suppression
YA functions (Rakoff-Nahoum et al., 2001). One common(Zhu and Ting, 2001). The observation was made that
feature is that most of the pathways utilized by patho-CIITA induction by IFN- can lead to the suppression
gens affect a more general target upstream of CIITAof genes that are known suppressive targets of this
expression, such as the Jak/Stat pathway, the USF-1cytokine. Hence, CIITA represents a dual-function fac-
transcription factor, IFN- receptor expression, andtor, both as a strong inducer of immune response genes,
other cytokines which can affect class II expression;and a repressor of general histone acetyltransferases
thus, the effects are far-reaching beyond MHC class IIfor certain genes that may not be of immediate use
regulation. Additionally, it was found that statin, a drugduring an IFN- response.
used in the treatment of heart disease to control lipidThe second question regarding CIITA and RFX is
levels, also decreases CIITA expression by interferingwhether they are indispensable for MHC class II expres-
with P4 function (Kwak et al., 2000). This raises thesion. Mice lacking functional CIITA or RFX5 have been
possibility that these drugs might be useful to regulateused to address this issue. CIITA/ mice are largely
immune activation involving the hyperexpression ofdevoid of class II, although some residual expression
class II antigens, as in autoimmune or autoinflammatoryremains. Analyses of two CIITA/ mice revealed sub-
disorders.stantial (20%) residual class II expression on dendritic
Both class II MHC and CIITA promoters exhibit poly-cells limited to the s.c. lymph nodes detected by immu-
morphisms that may be relevant to disease. This is notnohistochemistry (Williams, 1998). The analysis of a third
surprising, since the expression level or control dynam-CIITA/ strain revealed very low levels of class II mRNA
ics of a class II molecule could help to modulate theonly detected by RT-PCR, but not Northern hybridiza-
immune response (Baumgart et al., 1998). It may influ-tion, in the lymph nodes and spleen (Itoh-Lindstrom et
al., 1999). A more recent study utilized one of the ence cytokine profiles or the ratio of Th1 to Th2 re-
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